US2003235889A1PendingUtilityA1
Materials and methods involving conditional retention domains
Assignee: ARIAD GENE THERAPEUTICS INCPriority: Oct 19, 1998Filed: May 19, 2003Published: Dec 25, 2003
Est. expiryOct 19, 2018(expired)· nominal 20-yr term from priority
C07K 2319/71C07K 14/811C07K 2319/50C07K 2319/09C07K 14/4702A01K 2217/05C07K 2319/00C07K 2319/04C07K 2319/03C12N 15/625C07K 2319/75C07K 14/47C07K 2319/81C07K 2319/32C07K 2319/715C07K 2319/60C07K 14/62C12N 2799/022
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells expressing such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . A cell containing a recombinant nucleic acid encoding a fusion protein comprising at least one conditional retention domain (“CRD”) and at least one additional domain that is heterologous thereto.
2 . A cell of claim 1 wherein the fusion protein contains more than one CRD.
3 . A cell of claim 1 wherein the fusion protein molecules form aggregates with one another in the absence of a ligand which binds to the CRD.
4 . A cell of claim 1 wherein the CRD is derived from retinol binding protein, FKBP, IgM or alpha1-antitrypsin.
5 . A cell of claim 4 wherein the CRD comprises an FKBP domain with an amino acid replacement at F36 or W59.
6 . A cell of claim 5 wherein the CRD comprises an FKBP domain containing the mutation F36M or W59V.
7 . A cell of claim 1 wherein the heterologous domain of the fusion protein comprises the polypeptide sequence of a protein of interest.
8 . A cell of claim 7 wherein the protein of interest is a hormone, an endorphin, an antibody or an immunogen.
9 . A cell of claim 8 wherein the protein of interest is selected from the group consisting of insulin, parathyroid hormone and beta-endorphin.
10 . A cell of claim 1 wherein the fusion protein comprises an enzymatic cleavage site.
11 . A cell of claim 10 wherein the cleavage site is a furin cleavage site.
12 . A cell of claim 11 wherein the furin cleavage site comprises the amino acid sequence SARNRQKR (SEQ ID NO. 1).
13 . A cell of claim 1 wherein the fusion protein further comprises a secretory signal sequence.
14 . A cell of claim 13 wherein the secretory signal sequence is the signal sequence from the human growth hormone gene.
15 . A cell of claim 1 wherein the fusion protein comprises a secretory signal sequence, at least one conditional retention domain, a furin cleavage site, and a polypeptide sequence of interest.
16 . A cell of claim 15 wherein the fusion protein comprises a secretory signal sequence from human growth hormone, three F36M FKBP domains, a human stromelysin-3 furin cleavage site, and a polypeptide sequence of interest.
17 . A cell of claim 1 wherein the fusion protein comprises a lysosomal targeting signal.
18 . A cell of claim 1 wherein the cells are mammalian cells.
19 . A cell of claim 1 wherein the cells are of human origin.
20 . A cell of claim 1 wherein the cells are primary cells.
21 . A cell of claim 1 wherein the cells are in an animal.Join the waitlist — get patent alerts
Track US2003235889A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.